Introduction: Breast cancer patients, undergoing low-dose bone-modifying agent (LD-BMA) therapy for cancer treatment-induced bone loss (CTIBL), represent an emerging category at risk of Medication-Related (MRONJ) low (<1%) but not absent. However, data on their oral health status and quality of life related are currently limited. This single-center exploratory study aimed to assess oral health conditions, periodontal status, and oral health-related quality of life in non-metastatic breast cancer patients under LD-BMA therapy for CTIBL.Materials and methods: Forty patients were consecutively and unselectively enrolled and divided into two groups based on the duration of LD-BMA therapy (<3 years vs. ≥3 years). Oral examination by decayed-missing-filled teeth index (DMFT) and Periodontal Screening and Recording (PSR) was performed, and the OHIP-14 questionnaire was administered to assess their oral health-related quality of life.Results: No statistically significant differences were observed between the two groups in PSR, DMFT, or OHIP-14 scores. PSR scores indicating moderate-to-severe periodontal involvement (3–4) were reported in 73.3% of patients treated for <3 years and 70% of those treated ≥3 years. Mean DMFT values were 9.7 and 12.0, respectively. Although patients treated for ≥3 years reported higher OHIP-14 scores, this trend did not reach statistical significance. No cases of MRONJ were observed in the study groups.Conclusions: Patients affected by breast cancer receiving LD-BMA therapy for CTIBL and recruited in a preventive program appear to have a very low risk of MRONJ. Despite comparable clinical findings across treatment durations, longer LD-BMA therapy may be associated with a perceived reduction in oral well-being, possibly related to systemic and psychosocial burdens. These findings, with the limitation of a small sample size, support the implementation of individualized, risk-based dental and psychological preventive strategies, and reinforce the relevance of long-term dental surveillance in this under-explored population.

Mauceri, R., Coppini, M., Marchese, S.M., Mauceri, N., Coniglio, R., Nisi, M., et al. (2025). Oral health status and quality of life in female patients receiving low dose bone-modifying agents for cancer treatment-induced bone loss: a single-center exploratory study. FRONTIERS IN ORAL HEALTH, 6, 01-10 [10.3389/froh.2025.1683722].

Oral health status and quality of life in female patients receiving low dose bone-modifying agents for cancer treatment-induced bone loss: a single-center exploratory study

Mauceri, Rodolfo;Coppini, Martina
;
Mauceri, Nicola;Coniglio, Rita;Mauceri, Maria Elena;Valerio, Maria Rosaria;Campisi, Giuseppina
2025-10-31

Abstract

Introduction: Breast cancer patients, undergoing low-dose bone-modifying agent (LD-BMA) therapy for cancer treatment-induced bone loss (CTIBL), represent an emerging category at risk of Medication-Related (MRONJ) low (<1%) but not absent. However, data on their oral health status and quality of life related are currently limited. This single-center exploratory study aimed to assess oral health conditions, periodontal status, and oral health-related quality of life in non-metastatic breast cancer patients under LD-BMA therapy for CTIBL.Materials and methods: Forty patients were consecutively and unselectively enrolled and divided into two groups based on the duration of LD-BMA therapy (<3 years vs. ≥3 years). Oral examination by decayed-missing-filled teeth index (DMFT) and Periodontal Screening and Recording (PSR) was performed, and the OHIP-14 questionnaire was administered to assess their oral health-related quality of life.Results: No statistically significant differences were observed between the two groups in PSR, DMFT, or OHIP-14 scores. PSR scores indicating moderate-to-severe periodontal involvement (3–4) were reported in 73.3% of patients treated for <3 years and 70% of those treated ≥3 years. Mean DMFT values were 9.7 and 12.0, respectively. Although patients treated for ≥3 years reported higher OHIP-14 scores, this trend did not reach statistical significance. No cases of MRONJ were observed in the study groups.Conclusions: Patients affected by breast cancer receiving LD-BMA therapy for CTIBL and recruited in a preventive program appear to have a very low risk of MRONJ. Despite comparable clinical findings across treatment durations, longer LD-BMA therapy may be associated with a perceived reduction in oral well-being, possibly related to systemic and psychosocial burdens. These findings, with the limitation of a small sample size, support the implementation of individualized, risk-based dental and psychological preventive strategies, and reinforce the relevance of long-term dental surveillance in this under-explored population.
31-ott-2025
Mauceri, R., Coppini, M., Marchese, S.M., Mauceri, N., Coniglio, R., Nisi, M., et al. (2025). Oral health status and quality of life in female patients receiving low dose bone-modifying agents for cancer treatment-induced bone loss: a single-center exploratory study. FRONTIERS IN ORAL HEALTH, 6, 01-10 [10.3389/froh.2025.1683722].
File in questo prodotto:
File Dimensione Formato  
froh-6-1683722.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 366.49 kB
Formato Adobe PDF
366.49 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/692524
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact